AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 64 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $6,248,000 | -38.3% | 776,094 | -42.6% | 0.01% | -45.5% |
| Q4 2018 | $10,125,000 | -31.0% | 1,351,790 | -11.8% | 0.01% | -21.4% |
| Q3 2018 | $14,665,000 | -9.1% | 1,532,401 | +0.5% | 0.01% | -12.5% |
| Q2 2018 | $16,139,000 | +8.1% | 1,525,447 | +1.4% | 0.02% | +6.7% |
| Q1 2018 | $14,931,000 | +98.1% | 1,505,098 | +8.0% | 0.02% | +114.3% |
| Q4 2017 | $7,539,000 | +14.8% | 1,393,439 | +0.6% | 0.01% | 0.0% |
| Q3 2017 | $6,565,000 | +22.4% | 1,385,067 | -0.8% | 0.01% | +16.7% |
| Q2 2017 | $5,363,000 | -50.5% | 1,396,667 | -4.0% | 0.01% | -50.0% |
| Q1 2017 | $10,836,000 | +72.3% | 1,454,529 | +0.6% | 0.01% | +71.4% |
| Q4 2016 | $6,289,000 | -31.1% | 1,445,713 | +1.5% | 0.01% | -30.0% |
| Q3 2016 | $9,131,000 | +36.5% | 1,424,947 | +2.7% | 0.01% | +42.9% |
| Q2 2016 | $6,688,000 | – | 1,388,079 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
| Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
| Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
| Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
| Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
| Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
| Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
| Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
| Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
| Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |